Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Seres Therapeutics, Inc. (MCRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates"
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates",
"Seres Therapeutics, Inc. Corporate Presentation as of May 2023",
"Seres Therapeutics, Inc. SER-155 Phase 1b Cohort 1 Study Results Slide Presentation as of May 2023",
"Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome"
08/03/2022 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates"
05/04/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates"
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates"
08/03/2021 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates"
05/07/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 5, 2019 SERES THERAPEUTICS, INC. Delaware 001-37465 27-4326290 200 Sidney Street Cambridge, MA 02139 Registrant's Telephone Number, Including Area Code: 945-9626 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen...",
"Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update"
08/06/2019 8-K Quarterly results
05/02/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update"
11/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates"
08/02/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 2, 2018 SERES THERAPEUTICS, INC. Delaware 001-37465 27-4326290 200 Sidney Street Cambridge, MA 02139 Registrant's Telephone Number, Including Area Code: 945-9626 Not Applicable Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided...",
"Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates"
05/09/2018 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 9, 2018 SERES THERAPEUTICS, INC. Delaware 001-37465 27-4326290 200 Sidney Street Cambridge, MA 02139 Registrant's Telephone Number, Including Area Code: 945-9626 Not Applicable Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pu...",
"Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates",
"Seres Therapeutics, Inc. Corporate Slide Presentation as of May 9, 2018"
11/08/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress"
08/03/2017 8-K Quarterly results
Docs: "Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress"
05/04/2017 8-K Form 8-K - Current report
11/10/2015 8-K Form 8-K - Current report
08/06/2015 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy